•  
  •  
 

Article Type

Original Study

Abstract

Background Due to the possibility of spontaneous remission, invasive treatment in central serous chorioretinopathy (CSCR) is not to be commenced sooner than 3 months after onset of the disease. The aim of this work is to evaluate the effectiveness of subliminal diode-laser (SLDL) therapy for CSCR conducted 3–6 months after diagnosis. Aim The aim of the work is to study the effectiveness of using transfoveal subliminal diode-laser application in treatment of CSCR. Patients and methods The study included CSCR cases that last up to 1–3 months after acute onset of disease. All patients had transfoveal SLDL application and these patients were observed for 1 month and 3 months after SLDL treatment. Best-corrected visual acuity (BCVA) and retinal morphological alterations were the factors measured during the study. Results In 81.25% of cases, the subretinal fluid complete resolution was observed after therapy, BCVA improved dramatically. Early SLDL was associated with an improved end BCVA (P = 0.0005). The assessment in cases of nonresponding to SLDL demonstrated a decreased visual acuity than the baseline. Conclusions SLDL application is considered a good and safe treatment modality in management of CSCR, early treatment results in better visual outcomes such as improving VA, decreasing central macular thickness, and absorption of subretinal fluid.

Keywords

Central serous chorioretinopathy, subliminal diode laser, subretinal fluid

Download

Share

COinS